COMMUNICATION

Probing protein-protein and protein-substrate interactions in the dynamic membrane-associated ternary complex of Cytochromes P450, b5, and Reductase

Received 00th January 20xx,
Accepted 00th January 20xx

Katherine A. Gentry^a, G. M. Anantharamaiah^b and Ayyalusamy Ramamoorthy^a

DOI: 10.1039/x0xx00000x

Abstract: Cytochrome P450 (cytP450) interacts with two redox partners, cytP450 reductase and cytochrome-b₅, to metabolize substrates. Using NMR, we reveal changes in the dynamic interplay when all three proteins are incorporated into lipids nanodiscs in the absence and presence of substrates.

Cytochrome P450s (cytP450) are a ubiquitous superfamily of enzymes responsible for the metabolism of a variety of compounds from vitamins to fatty acids to over 70% of the drugs on the pharmaceutical market.^[1-5] Per turn of its catalytic cycle which requires two electrons, cytP450 inserts a molecule of activated oxygen into a hydrophobic substrate. Both electrons can be provided by cytochrome P450 reductase (CPR), cytP450's obligate redox partner, or the second can be donated by cytochrome b₅ (cytb₅).^[6]

CPR is an 80 kDa protein that consists of the FAD/NADPH binding domain, the FMN binding domain (FBD), a linker region connecting the two flavin domains, and an N-terminal transmembrane domain.^[5, 7] After being reduced by NADPH, electrons flow from the FAD binding domain to FMN in the FBD which then directly donates the electrons to the heme in the active site of cytP450. In this study, we utilize a truncated version of CPR, the full-length FBD (flFBD), consisting of only the FBD along with the N-terminal transmembrane domain. This flFBD domain has been used previously as the minimal necessary domain of CPR to interact with cytP450^[8-10].

Cytb₅, the third protein of this ternary complex, is a ~15.7 kDa protein only capable of donating the second electron to cytP450 because of the disparity in redox potentials between it and ferric cytP450.^[5, 11, 12] Cytb₅ has been shown to increase, decrease, or do nothing to cytP450's metabolism depending on the isoform of cytP450 and the type of substrate involved.^[2, 13, 14] In some cases, such as that of cytP450 17A1, cytb₅ is known to favor a specific reaction and product formation.^[15, 16, 17] Due to the mystery still surrounding cytb₅'s functional properties, we further investigated cytb₅'s role in regulating cytP450 drug metabolism.

All three proteins, cytP450, cytb₅, and flFBD, contain single transmembrane helices that anchor them to the membrane (Figure 1A). In cytP450's case, even the globular, 'soluble' domain, specifically the F/G-loop, interacts with the lipid bilayer.^[18-20] The presence of a lipid bilayer has been shown to influence these

cytP450-redox partner protein-protein interactions both through dictating favorable orientations for complex formation, increasing or decreasing electron transfer rates and affecting metabolism of substrates, and altering the spin state shifts of the heme group of cytP450 when the redox partner is present.^[2, 21, 22] In order to study this ternary complex in a lipid environment, herein we utilized nanodiscs (ND). Using 4F peptides as the scaffold belt for the NDs is very favorable for this ternary complex because it creates very flexible nanodiscs that are accommodating for the stepwise addition of single-pass transmembrane proteins. Our previous studies have illustrated this ability with two membrane proteins.^[10]

As substrates have been shown to have a sizeable impact on strengthening the complex interactions between cytb₅ and cytP450, we chose five substrates to probe this complex's strength. These substrates were chosen due to their range in hydrophobicity although as cytP450 substrates, they are all hydrophobic in nature, and availability of cytP450 crystal structures solved in the presence of these compounds. They are: butylated hydroxytoluene (BHT; LogP = 5.3), bifonazole (BFZ; LogP = 4.8), benzphetamine (BZ; LogP = 4.1), 4-(4-Chlorophenyl)-1H-imidazole (4-CPI; LogP = 2.4), and 1-(4-Chlorophenyl)-imidazole (1-CPI; LogP = 2.3). Herein, we also examined the role of membrane and various substrates on the interplay between cytP450 and its two redox partners.

In order to study the ternary complex in lipid NDs, each full-length protein was expressed, purified and characterized as detailed in the SI. For this study, the 55 kDa cytP450 isoform that was utilized is cytP450 2B4, a rabbit homolog with 76% sequence identity to human cytP450 2B6.^[23] Sequential incorporation of the three

Figure 1. Reconstitution of cytochrome proteins in a lipid nanodisc. (A) A schematic of the three cytochrome proteins incorporated into a nanodisc. (B) and (C) both display the formation of protein-protein complexes into nanodiscs with stepwise incorporation of proteins into the nanodisc through SEC (B) and DLS (C).

^a Biophysics and Department of Chemistry, Biomedical Engineering, Macromolecular Science and Engineering, University of Michigan, Ann Arbor, MI 48109-1055 (USA).

^b Department of Medicine, UAB Medical Centre, Birmingham, Alabama, 35294 (USA).

† E-mail: ramamoor@umich.edu; kgentry@umich.edu

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/x0xx00000x

proteins was accomplished over the course of three days using 4F-DMPC NDs that were purified through size exclusion chromatography (SEC). Two versions of the ternary complex were assembled: one with cytb₅ incorporated into the ND first, then cytP450, and then flFBD, called “cytb₅-ternary complex” and the other with flFBD incorporated into the ND first, then cytP450, and then cytb₅, called “flFBD-ternary complex”. Reconstitution of these proteins into NDs was accomplished by the mixing of empty NDs and protein, incubating overnight, purifying by SEC, and characterizing their size by dynamic light scattering (DLS). On the second day, one molar equivalent of cytP450 2B4 was added to form complexes of cytb₅-cytP450 or flFBD-cytP450 in NDs. On the third day, the other redox partner was added to the samples in order to make the *cytb₅-ternary complex* or *flFBD-ternary complex* for a final protein ratio of 1:1:1. In Figure 1B and 1C, a gradual increase in size is displayed while creating the *flFBD-ternary complex* as seen by the increase in the Stoke radius in DLS or elution time growing shorter in SEC after the addition of proteins to empty NDs (blue), NDs+flFBD (green), NDs+flFBD+cytP450 (black), and NDs+flFBD+cytP450+cytb₅ (red). Figure S1A and S1B show the *cytb₅-ternary complex* formation via SEC and DLS. Previous work has revealed that substrates drive the

formation of a strong complex between cytb₅ and cytP450 in solution as well as in ternary complex systems with cytb₅, cytP450, and FBD.^[24-26] Complex formation between ¹⁵N-labeled cytb₅ and cytP450 was monitored through ¹⁵N/¹H TROSY HSQC NMR experiments by measuring the signal intensities and linewidths of cytb₅'s amide ¹⁵N-¹H peaks. As the chemical environment around amide N-H changes upon binding to cytP450, a sizeable change in linewidth and intensity of resonances were observed in the NMR spectra (Figures S2-S14).

Figure 2 reports the average signal intensity observed for residues clustered on the lower left of cytb₅. These residues (N62-R73) are highlighted in blue in the inset of Figure 2 and have been identified as important residues that bind to cytP450.^[27] As this lower cleft is highly involved in binding to cytP450, it is a good marker to probe if cytb₅ is bound to cytP450. Upon the addition of cytP450 (Figure 2, orange) to the ¹⁵N-labeled cytb₅, the overall signal intensity of the lower cleft residues of cytb₅ drops to about ~52% of the original intensity. Intriguingly, when various substrates were added to the cytb₅-cytP450 complex, the binding is not strengthened based on the lack of changes observed for the signal intensities (Figure 2, Figure S15). This lack of substrate effect is not completely surprising because the complex is already showing a tight binding due to the presence of the lipid membrane in the nanodiscs in comparison to the lipid-free condition as reported previously.^[24] One hypothesis as to why the substrates do not increase the complex strength is that the hydrophobic compounds do partition into the lipid bilayer. As the drugs have another way of increasing hydrophobic contacts than promoting binding between the two proteins, the substrate-induced changes in the protein-protein interaction does not happen as strongly as observed in the absence of lipids. Some drugs like BFZ and BZ, slightly dislodge the complex between cytb₅ and cytP450 (Figure 2 light green, light blue) as shown by the slight increase in signal intensity. While we do not know what the cause for this disruption is, there could be several things happening. As hydrophobic compounds partition into the membrane, they could be interacting with the transmembrane domains of the proteins or with other parts of cytP450.

Upon the addition of flFBD to the ND containing cytb₅ and cytP450, we see an increase in signal intensity globally, but the cytb₅ residues do not return to the same intensity level as observed for NDs containing cytb₅ alone. In the presence of substrates, flFBD is unable to greatly disrupt the interaction between cytb₅ and cytP450. Without a substrate present, flFBD can dislodge cytb₅ from a complex with cytP450 which is demonstrated by the return of about 85% of the starting signal intensity. By dislodging cytb₅, we mean that flFBD is able to disrupt the complex between cytb₅ and cytP450 and interfere so some of the cytb₅ is no longer bound to cytP450. Cytb₅ does not leave the ND. Substrates can keep cytb₅ and cytP450 bound to one another and make flFBD less capable of disrupting the complex. Drugs with highest to lowest ability of maintaining complex formation are in the following order: BZ, BFZ, BHT, 1-CPI, 4-CPI. Looking closely at one of the residues identified in binding of cytb₅ to cytP450, Serine 69, we can see in Fig. 2 that its signal intensity decreases upon the addition of cytP450. After the addition of drugs to the cytb₅-cytP450 ND complex, slight changes occur in the signal intensity. Once flFBD was added, varying levels of signal intensities were restored. Figure S15 displays the extracted linewidths of S69 to

illustrate the broadening of the signal upon the addition of cytP450 and the partial restoration after the addition of flfBD.

From our previous study [24], it was shown that cytb₅ can dislodge flfBD from the flfBD-cytP450 complex. We were curious as to how the membrane would affect cytb₅'s ability to disrupt the flfBD-cytP450 complex as it provides both a more native membrane environment and a spatial constraint (Figure 3). Uniformly ¹⁵N-labeled flfBD was expressed, purified, and reconstituted into 4F-DMPC NDs. A ¹⁵N/¹H TROSY-HSQC spectrum was acquired of ¹⁵N-flfBD in ND alone (red). Stepwise reconstitution was done to incorporate cytP450 2B4 into the flfBD containing NDs and a spectrum was obtained (orange). Each of the five drugs chosen were incubated with the complex of flfBD-cytP450 (4-CPI, pink; BFZ, yellow; BHT, green; 1-CPI, blue; BZ, purple) and then TROSY-HSQC spectra were obtained (Figures S16-S28). Finally, cytb₅ was incorporated into the flfBD-cytP450-ND with and without substrates.

The overall signal intensity of the flfBD residues was monitored as the protein complexes were formed and broken. A decrease in the signal intensity upon the addition of cytP450 indicates that a complex was formed between flfBD and cytP450. After the addition of a substrate, no significant difference in complex strength was observed. Substrates have not been shown to dramatically increase the affinity of cytP450 for flfBD, so this result was not surprising. Both 4-CPI and BFZ marginally increased the complex strength while BHT and BZ's addition did not strengthen the complex, and BZ weakened it a little. The addition of 1-CPI, however, significantly increased the

complex formation which is shown in Figure 3 (blue) and Figure S33.

Once cytb₅ was incorporated into NDs, it does show the ability to disrupt the flfBD-cytP450 complex. This is demonstrated by the restoration of signal intensities of flfBD residues, particularly, looking at Glycine 89 (in Figure 3) which is a residue in loop 1 of flfBD which coordinates the FMN cofactor and has been previously implicated in binding to cytP450.[10] By analyzing the signal intensity and linewidth of this residue, we obtained information about its chemical environment and the timescale of its dynamics. Upon addition of cytP450, the resonance broadens, and the intensity decreases as can be seen in Figure 3 (orange). Adding in a substrate did not significantly change the peak intensity for any of the substrates chosen for this residue of flfBD. Upon cytb₅ incorporation into the nanodisc, G89's linewidth and signal intensity were greatly restored (bottom row, Figure 3). Meanwhile other residues on flfBD that are farther away from the interaction like S123, undergo some changes but these are much more consistent with the nanodisc containing a larger complex's tumbling rate rather than direct interaction with cytP450. Figure 4 displays the extracted linewidths of G89 and other important loop residues to illustrate the broadening of the signal upon the addition of cytP450 to the flfBD in ND and the restoration after the addition of cytb₅ to the complex in NDs.

Studying the ternary complexes incorporated into lipid nanodiscs allowed us to capture some interesting behavior of cytP450's preference for its redox partners. While cytb₅ is still able to dislodge flfBD from a complex with cytP450, it is not to as great of an extent as it could in the absence of lipids in solution. Having the three proteins being spatially confined in a nanodisc could contribute to keeping flfBD bound to cytP450 better, but it is currently unclear to assign that to the influence of lipids on complex strength or the physical restraint of motion. The variety of substrates utilized in this study all behaved similarly in regard to forming a stronger complex with cytb₅-cytP450, however, it was much less of an effect than what was seen in lipid-free solution [23]. flfBD was able to dislodge cytb₅ from its complex with cytP450, but not completely. The highest effect was seen without substrates and flfBD was only able to slightly disrupt the complex in the presence of substrates.

One of the more interesting comparisons from this study includes the two inhibitors 4-CPI and 1-CPI in the presence of ¹⁵N-flfBD-ternary complex. In agreement with Zhao et al., we have found major differences in the interactions between cytP450 and flfBD in the presence of 1-CPI versus 4-CPI, even with their structural similarity.[28] Crystal structures of cytP450 2B4 have been solved in the presence of both inhibitors which revealed very different active site conformations. The calculated active site volume for 4-CPI was 200 Å versus 280 Å for 1-CPI bound cytP450 2B4. Our NMR data reveal that there is an increased binding and tighter complex formation between cytP450 2B4 and flfBD after the 1-CPI inhibitor addition which is in agreement with the ITC experiments performed by Zhao et al.[28] Figure 4 and Figures S29-S31 show the average signal intensities for each of the four loops that coordinate the FMN cofactor. The residues in each loop are listed in Supplemental Table 1. In the presence of 4-CPI binding to cytP450, all loops are only slightly affected. In comparison, in the presence of 1-CPI binding to cytP450, loop 2 on flfBD is strongly affected. Even the addition of cytb₅ does not completely restore the signal intensity of loop 2 in the 1-CPI complex sample.

Interestingly this data reveals more residues binding of flfBD to cytP450 which was recently reported.[9] In the presence of membrane, flfBD binds to cytP450 with all four loops that surround the FMN. The major takeaway from this study is that in the presence of lipid membrane, this dynamic interplay approaches what is

thought to be more physiological behavior. Without being reconstituted in a lipid nanodisc, flFBD cannot dislodge cytb₅ from binding to cytP450. Physiologically, if cytb₅ is bound to cytP450 before the first electron can be donated by CPR, then the catalytic cycle ceases. Cytb₅ is incapable of donating the first electron due to the disparity in redox potentials. Without the dynamic exchange between redox partner binding, drug metabolism slows or even halts. Here we see signs that add to the prevailing hypothesis that cytb₅ plays not only an electron donating role, but also has conformational contributions to influencing cytP450's behavior. A myriad of studies has illustrated that while holo-cytb₅ has the largest effect, mainly an increase, in substrate turnover, apo-cytb₅ as well as other metal substituted porphyrins, also have a sizeable contribution to cytP450's substrate metabolism that is independent of the electron transfer ability.^[29-31] In this study, we carry out all NMR experiments with oxidized proteins and an absence of reductants. Due to the inability of cytb₅ to donate electrons to cytP450, we can assume that some conformational effects are at play.

In conclusion, as we have shown through NMR results, the dynamic exchange between cytP450, flFBD, and cytb₅ is highly affected by the presence of a lipid environment. We see cytb₅ dominating the competition by weakening the flFBD's complex with cytP450. In the membrane environment, flFBD is more able to disrupt the cytb₅-cytP450 complex than in the absence of lipids albeit not completely. The addition of substrates to this ternary complex reveals differences in redox partner binding to cytP450 as well as the skewing of the interplay to favor cytb₅ over flFBD binding. This study emphasizes the need to study these proteins in a membrane environment in order to more fully capture their native behaviors.

Acknowledgements

This study was supported by NIH funding (GM084018 to A.R.).

Conflicts of interest

There are no conflicts to declare.

Notes and references

1. F. P. Guengerich, *Mol. Interventions*, 2003, **3**, 194.
2. C. Barnaba, K. Gentry, N. Sumangala and A. Ramamoorthy, *F1000 Research*, 2017, **6**, 662.
3. F. P. Guengerich, *Chem. Res. Toxicol.*, 2008, **21**, 70.
4. F. P. Guengerich, Z. L. Wu and C. J. Bartleson, *Biochem. Biophys. Res. Commun.*, 2005, **338**, 465.
5. U. H. Dürr, L. Waskell and A. Ramamoorthy, *Biochim. Biophys. Acta*, 2007, **1768**, 3235.
6. S. C. Im and L. Waskell, *Arch. Biochem. Biophys.*, 2011, **507**, 144.
7. M. Wang, D. L. Roberts, R. Paschke, T. M. Shea, B. S. Masters, and J. J. Kim, *Proc. Natl. Acad. Sci. U. S. A.*, 1997, **94**, 8411.
8. D. F. Estrada, J. S. Laurence and E. E. Scott, *J. Biol. Chem.*, 2016, **291**, 3990.
9. M. Mahajan, T. Ravula, E. Prade, G. M. Anantharamaiah, A. Ramamoorthy, *Chem. Commun.*, 2019, **55**, 5777.
10. E. Prade, M. Mahajan, S.-C. Im, M. Zhang, K. A. Gentry, G. M. Anantharamaiah, L. Waskell, A. Ramamoorthy, *Angew. Chem. Int. Ed. Engl.*, 2018, **57**, 8458.
11. H. Zhang, D. Hamdane, S. C. Im and L. Waskell, *J. Biol. Chem.*, 2008, **283**, 5217.
12. Y. Yang, H. Zhang, D. Usharani, W. Bu, S. Im, M. Tarasev, F. Rwere, N. M. Pearl, J. Meagher, C. Sun, J. Stuckey, S. Shaik, and L. Waskell, *Biochemistry*, 2014, **53**, 5080.
13. H. Yamazaki, M. Nakamura, T. Komatsu, K. Ohvama, N. Hatanaka, S. Asahi, N. Shimada, F. P. Guengerich, T. Shimada, M. Nakajima, and T. Yokoi, *Protein Expression Purif.*, 2002, **24**, 329.
14. J. Y. Chiang, *Arch. Biochem. Biophys.*, 1981, **211**, 662.
15. J. B. Schenkman and I. Jansson, *Pharmacol. Ther.*, 2003, **97**, 139.
16. D. F. Estrada, A. L. Skinner, J. S. Laurence and E. E. Scott, *J. Biol. Chem.*, 2014, **289**, 14310.
17. R. Duggal, I. G. Denisov, S. G., Sligar, *FEBS Lett.*, 2018, **592**, 228.
18. B. C. Monk, T. M. Tomasiak, M. V. Keniya, F. U. Huschmann, J. D. Tyndall, J. D. O'Connell 3rd, R. D. Cannon, J. G. McDonald, A. Rodriguez, J. S. Finer-Moore, R. M. Stroud, *P.N.A.S.*, 2014, **111**, 3865.
19. D. R. McDougale, J. L. Baylon, D. D. Meling, A. Kambalyal, Y. V. Grinkova, J. Hammernik, E. Tajkhorshid, A. Das., *Biochem. Biophys. Acta Biomembr.*, 2015, **1848**, 2460.
20. J. L. Baylon, I. L. Lenov, S.G. Sligar, and E. Tajkhorshid, *J. Am. Chem. Soc.*, 2013, **135**, 8542.
21. T. Ravula, C. Barnaba, M. Mahajan, G. M. Anantharamaiah, S.-C. Im, L. Waskell, A. Ramamoorthy, *Chem. Commun.* 2017, **53**, 12798.
22. I. G. Denisov, S. G. Sligar, *Biochim. Biophys. Acta* 2011, **1814**, 223.
23. E. E. Scott, M. A. White, Y. A. He, E. F. Johnson, C. D. Stout, J. R. Halpert, *J. Biol. Chem.*, 2004, **279**, 27294.
24. K. A. Gentry, M. Zhang, S.-C. Im, L. Waskell, A. Ramamoorthy, *Chem. Commun.* 2017, **54**, 5780.
25. M. Zhang, R. Huang, R. Ackerman, S.-C. Im, L. Waskell, A. Schwendeman, A. Ramamoorthy, *Angew. Chem. Int. Ed. Engl.*, 2016, **55**, 4497.
26. M. Zhang, S. V. Le Clair, R. Huang, S. Ahuja, S.-C. Im, L. Waskell, A. Ramamoorthy, *Sci. Rep.*, 2015, **5**, 8392.
27. S. Ahuja, N. Jahr, S.-C. Im, S. Vivekanandan, N. Popovych, S. Le Clair, R. Huang, R. Soong, J. Xu, K. Yamamoto, R. P. R. Nanga, A. Bridges, L. Waskell, A. Ramamoorthy, *J. Biol. Chem.*, 2013, **288**, 22080.
28. Y. Zhao, L. Sun, B. K. Muralidhara, S. Kumar, M. A. White, C. D. Stout, J. R. Halpert, *Biochemistry*, 2007, **46**, 11559.
29. M. B. Murataliev, V. M. Guzov, F. A. Walker, R. Feyereisen, *Insect Biochem. Mol. Biol.*, 2008, **38**, 1008.
30. H. Yamazaki, T. Shimada, M. V. Martin, F. P. Guengerich, *J. Biol. Chem.*, 2001, **276**, 30885.
31. H. Yamazaki, M. Nakamura, T. Komatsu, K. Ohyama, N. Hatanaka, S. Asahi, N. Shimada, F. P. Guengerich, T. Shimada, M. Nakajima, T. Yokoi, *Protein Expr. Purif.*, 2002, **24**, 329.